York Charles N II's Form 4 filing
Day One Biopharmaceuticals, Inc. (DAWN) · filed Feb 18, 2026
- Accession no.
- 0001655962-26-000004
- Filed
- Feb 18, 2026
- Trade date
- Feb 15-17, 2026
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $70.4K. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| York Charles N IICIK 0001655962 | Officer (COO and CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +2,250 | – | – | 296,965 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +6,625 | – | – | 303,590 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +6,625 | – | – | 310,215 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseAcquired | +7,875 | – | – | 318,090 | Direct | |
| Feb 17, 2026 | Common Stock | SSaleDisposed | −6,065 | $11.60 | −$70,354 | 312,025 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −2,250 | $0.00 | $0 | 6,750 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −6,625 | $0.00 | $0 | 46,375 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −6,625 | $0.00 | $0 | 72,875 | Direct | |
| Feb 15, 2026 | Common Stock | MOption exerciseDisposed | −7,875 | $0.00 | $0 | 118,125 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.